XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and contingencies - Neurocrine Collaboration Agreement - (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Jun. 30, 2019
USD ($)
shares
Mar. 31, 2019
USD ($)
item
$ / shares
shares
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Allocation of Transaction Price          
Revenue recognized     $ 3,632    
Deferred revenue     40,057   $ 43,689
Related party collaboration receivable     4,253   $ 8,012
Neurocrine | FA Program          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of profit or loss under co-co option   60.00%      
Neurocrine Collaboration Agreement          
Allocation of Transaction Price          
Related party collaboration receivable     4,300    
Neurocrine Collaboration Agreement | VY-AADC          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of profit or loss under co-co option   50.00%      
Percentage of profit or loss under co-co option after paying rate-shifting fee   45.00%      
Neurocrine Collaboration Agreement | FA Program          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of profit or loss under co-co option   40.00%      
Neurocrine Collaboration Agreement | Neurocrine          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of collaboration programs | item   4      
Number of discovery programs | item   2      
Programs added later | item   2      
Number of targets | item   8      
Upfront payment $ 115,000 $ 115,000      
Purchase of common stock, shares | shares 4,179,728 4,179,728      
Purchase of common stock $ 5,000 $ 50,000      
Price per share | $ / shares   $ 11.9625      
Aggregate maximum milestone payments to be received from collaborative partner   $ 170,000      
Estimated cost reimbursement 431,100   270,200    
Termination period   10 years      
Period of advance notice for termination prior to first commercial sale   180 days      
Period of advance notice for termination after first commercial sale   1 year      
Discount related to equity investment 27,600        
Equity investment 50,000        
Allocation of Transaction Price          
Allocation of variable consideration     270,208    
Allocation of fixed consideration 92,400   92,382    
Revenue recognized     6,500 $ 14,500  
Cumulative catch up of revenue recognized     900    
Deferred revenue     40,100    
Related party collaboration receivable     4,300    
Costs to obtain collaboration agreement     800    
Consideration received $ 5,000        
Neurocrine Collaboration Agreement | Neurocrine | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of reduction in royalty payments   50.00%      
Neurocrine Collaboration Agreement | Neurocrine | VY-AADC          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of profit or loss under co-co option   50.00%      
Rate-shifting fee   $ 35,000      
Percentage of profit or loss under co-co option after paying rate-shifting fee   55.00%      
Allocation of Transaction Price          
Allocation of variable consideration     53,397    
Allocation of fixed consideration     49,045    
Neurocrine Collaboration Agreement | Neurocrine | FA Program          
Allocation of Transaction Price          
Allocation of variable consideration     80,408    
Allocation of fixed consideration     20,647    
Neurocrine Collaboration Agreement | Neurocrine | Discovery and FA Programs          
Allocation of Transaction Price          
Allocation of fixed consideration     42,200    
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 1          
Allocation of Transaction Price          
Allocation of variable consideration     69,572    
Allocation of fixed consideration     14,443    
Neurocrine Collaboration Agreement | Neurocrine | Discovery program 2          
Allocation of Transaction Price          
Allocation of variable consideration     66,831    
Allocation of fixed consideration     $ 8,247    
Neurocrine Collaboration Agreement | Neurocrine | Development and regulatory milestones | FA Program          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Aggregate maximum milestone payments to be received from collaborative partner   $ 195,000      
Neurocrine Collaboration Agreement | Neurocrine | Development and regulatory milestones | Discovery program 1          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Aggregate maximum milestone payments to be received from collaborative partner   130,000      
Neurocrine Collaboration Agreement | Neurocrine | Commercial Milestone          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Per Milestone, maximum milestone payments to be received from collaborative partner   275,000      
Aggregate maximum milestone payments to be received from collaborative partner   $ 1,100,000